Bayer’s Dicamba Hit Tests Patience of Frustrated Investors
- Jurors award Missouri farmer $265 million for peach orchards
- Chemical company is already trying to settle Roundup suits
This article is for subscribers only.
Bayer AG’s loss in the first U.S. trial over the herbicide dicamba is set to test the patience of investors who’ve stuck with the company through the dark days of its Roundup crisis.
Most will probably hang on for now, since their investment is based on the assumption that Bayer is undervalued in the face of a hurricane of lawsuits claiming that best-selling weed killer Roundup causes cancer. Adding dicamba to the legal storm -- a chemical accused of killing plants, not people -- probably won’t change that calculus, according to Alistair Campbell, an analyst at Liberum Capital. And Bayer is sharing the potentially multibillion-dollar headache in this case with BASF SE.